XNCR shorts hold firm as earnings loom and retail attention spikes

Xencor heads into its November 6 earnings print with short sellers sitting on a large position, the stock rallying sharply on the week, and retail attention running at a level rarely seen in its own history.

The most striking contradiction in this setup is the disconnect between the lending market and the short interest level itself. Short interest is high at 22.9% of the free float, up roughly 10% over the past month from around 14.2 million shares to 16.4 million. Yet borrowing conditions could hardly be easier. Cost to borrow is just 0.45%, barely above zero, and availability has widened dramatically over the past two weeks: it was around 300% to 350% through most of September and early October, then ballooned to over 2,600% by October 9, and is now back at 1,106%. That mid-October spike likely reflects a wave of share recalls or new lending supply entering the pool. The practical read is that while a significant short position is in place, there is no squeeze pressure whatsoever. Shorts are not being squeezed out and new shorts face almost no friction entering.

Options traders have turned modestly more defensive as the stock rallied. The put/call ratio is running at 0.53, about 1.3 standard deviations above its 20-day average of 0.43. That is elevated but not extreme, especially given the 52-week range runs all the way to 3.43 on the high end. The current reading looks more like normal hedging ahead of a binary catalyst than any pronounced directional bet.

The Street is broadly constructive but with a visible split on the upside case. Wedbush reiterated its Outperform and $30 target this morning, one day after the stock's 7.5% single-day gain. Earlier in October, Truist raised its target to $29 from $27, maintaining Buy. Barclays lifted to $35 from $27 in September while keeping Overweight. Against that, BofA is Neutral at $26 and JPMorgan is also Neutral at $21, the most cautious target among active analysts. The mean target across the group is $31.42 against a current price of $24.94, implying around 26% to the consensus. The bull case rests on XmAb819 data at ESMO and the broader oncology and immunology pipeline, backed by cash guidance of $420 to $440 million with runway through 2028 and growing Ultomiris royalty income. The bear case centres on the narrow path to registration: a response rate below 20% or median PFS under five months in ccRCC would effectively close the planned 2027 registrational study and expose the company's dependence on collaboration revenue before any wholly owned product reaches commercialisation.

One unusual signal this week is retail attention. The ORTEX Wikipedia views tracker, which measures attention against the company's own 90-day history across English Wikipedia article views and ORTEX stock page visits, is running at a z-score of 6.3. That is an extreme reading by any measure and likely reflects the stock's sharp move attracting fresh retail eyeballs rather than anything fundamental. It is worth noting as context for the price action but carries no established link to Xencor's reported figures.

Institutional ownership is concentrated in biotech-specialist and passive hands. BlackRock holds around 18.4% and State Street added roughly 600,000 shares in the quarter to September 30. T. Rowe Price added close to 800,000 shares in the same period. BVF Partners, the specialist biotech activist fund, filed a 13G in February disclosing a 9.99% position. No Schedule 13D has been filed, so there is no registered activist intent, but BVF's presence at that scale is notable given the fund's history of engagement in clinical-stage biotechs. As always with 13D/G disclosures, stakes are as-last-disclosed around the 5% threshold and a holder can fall below without a further filing.

Post-earnings price reactions over the past four prints have been consistently positive on the day, ranging from 0.4% to 4.9%, but the five-day window tells a more mixed story: two prints were followed by double-digit five-day gains while one ended down nearly 9%. The next print on November 6 is therefore less about the immediate day-one move and more about whether XmAb819 efficacy data justifies advancing to a Phase 3 registrational study, a binary outcome the short position's size and the options defensive tilt both reflect.